Skip to main content
Premium Trial:

Request an Annual Quote

Serologicals to Lay Off 36 Staffers as Part of Restructuring

NEW YORK, July 18 (GenomeWeb News) - Serologicals will lay off 23 positions in its Lake Placid, NY, business and offer relocation options to 39 additional employees, GenomeWeb News has learned.


The job cuts, which also include 13 staffers in the company's Temecula, Calif., facility, is part of Serologicals' efforts to cut costs in its research segment by $3 million to $3.5 million a year. Employees offered relocation would mainly work in Serologicals' Chemicon International business, located in Temecula.


As GenomeWeb News reported last week, the Atlanta-based company said it will integrate several functions of its Upstate and Chemicon units through the remainder of the year, including business segment management, R&D/business development, marketing, technical support, scientific sourcing, intellectual property/licensing, and finance and accounting.


Serologicals said it expects to incur between $2 million and $3 million in one-time costs related to severance payments, retention payments, and relocation costs that it will record in the third quarter.


Serologicals, which has more than 1,000 employees worldwide, operates three companies: Chemicon International, based in Temecula; Upstate Group, based in Charlottesville, Va.; and Celliance, based in Atlanta.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.